| P50 | author | Cristina Scarpazza | Q62058593 |
| | Maria Pia Sormani | Q84058299 |
| P2093 | author name string | Ruggero Capra | |
| | Luca Prosperini | |
| | Simonetta Gerevini | |
| | Lucia Moiola | |
| | Nicola De Rossi | |
| | Italian PML group | |
| P2860 | cites work | No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. | Q38754429 |
| | Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant | Q40792696 |
| | Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay | Q40994617 |
| | MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. | Q41361912 |
| | HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. | Q41509979 |
| | Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome | Q41906877 |
| | Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis | Q42268433 |
| | Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? | Q43897444 |
| | Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere | Q44719955 |
| | Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. | Q45363437 |
| | A controlled trial of natalizumab for relapsing multiple sclerosis | Q48414534 |
| | To PLEX or not to PLEX in natalizumab-associated PML. | Q54430369 |
| | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| | Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring | Q22242013 |
| | Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain | Q24619923 |
| | Progressive multifocal leukoencephalopathy: current treatment options and future perspectives | Q26776236 |
| | Neurological immune reconstitution inflammatory response: riding the tide of immune recovery | Q28082309 |
| | Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 |
| | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry | Q28555138 |
| | Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy | Q30689194 |
| | Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial? | Q30787765 |
| | PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids | Q33398308 |
| | Progressive multifocal leukoencephalopathy in HIV-1 infection | Q33506561 |
| | Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 |
| | Progressive multifocal leukoencephalopathy: why gray and white matter | Q34307762 |
| | A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. | Q34328813 |
| | Persistence and pathogenesis of the neurotropic polyomavirus JC | Q34459843 |
| | Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 |
| | Metabolic profile of PML lesions in patients with and without IRIS: an observational study | Q36198630 |
| | Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 |
| | Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? | Q36544721 |
| | Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function | Q37180600 |
| | Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 |
| | Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). | Q37779049 |
| | Progressive multifocal leukoencephalopathy in multiple sclerosis | Q38153637 |
| | Progressive multifocal leukoencephalopathy therapy | Q38250227 |
| P433 | issue | 5 | |
| P304 | page(s) | 697-705 | |
| P577 | publication date | 2017-10-31 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy | |
| P478 | volume | 82 | |